Progression and CSF Inflammation after Eradication of Oligoclonal Bands in an MS Patient Treated with Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma

P. Braendstrup, A.R. Langkilde, K. Schreiber, M. Ravnborg, F. Sellebjerg, L. Vindeløv

Key Words
Multiple sclerosis · Allogeneic hematopoietic cell transplantation · Disease-modifying therapies · CXCL13 · Matrix metalloproteinase-9 · Oligoclonal bands

Abstract
Background: Allogeneic hematopoietic cell transplantation (allo-HCT) has been proposed as treatment for multiple sclerosis (MS) and other autoimmune diseases.
Aims: To describe the effects of allo-HCT on the course of MS in a 49-year-old woman with longstanding progressive MS who was treated with allo-HCT for follicular lymphoma.
Methods: Non-myeloablative conditioning allo-HCT, examination for IgG oligoclonal bands and measurement of CXCL13 and matrix metalloproteinase-9 (MMP-9) concentration in the cerebrospinal fluid (CSF).
Results: Despite the disappearance of oligoclonal bands in CSF, disease progression and CSF inflammation was observed.
Conclusions: We hypothesize that CXCL13 and MMP-9 detected in CSF may reflect ongoing, pathogenic immune activation even after the eradication of intrathecal IgG synthesis. This suggests that progressive MS may depend more on innate than on adaptive immune activation.

Peter Brændstrup
Department of Hematology, Rigshospitalet
Blegdamsvej 9, DK–2100 Copenhagen (Denmark)
Tel. +45 2878 6302, E-Mail peter.braendstrup@gmail.com
Introduction

Autologous hematopoietic cell transplantation (auto-HCT) treatment for multiple sclerosis (MS) involves high-dose chemotherapy (immunosuppression) that requires 'rescue' of the hematopoietic system with blood stem cells [1, 2]. In allogeneic hematopoietic cell transplantation (allo-HCT) the graft is obtained from an HLA-matched donor. In allo-HCT with myeloablative conditioning high-dose chemo-radiotherapy is given with the aim of eradicating the last tumor cell. Allo-HCT with non-myeloablative conditioning exploits the fact that the curative effect is mainly achieved by the ability of the donor immune system to eradicate recipient hematopoietic cells including malignant cells. The conditioning is mild and given only to prevent rejection of the donor cells [3].

Case Presentation

In July 2006 we treated a 49-year-old woman with MS with non-myeloablative conditioning allo-HCT for follicular lymphoma grade 1–2, stage IV. Prior to the transplant the lymphoma was brought into complete remission with chemotherapy. The graft consisted of peripheral blood stem cells from an HLA-identical sister (table 1).

Relapsing-remitting MS with onset in 1985 evolved into secondary progressive MS from 2000. She did not want immunomodulatory treatment at any time. She had no MS relapses from 2004 to 2006. Prior to HCT her expanded disability status scale (EDSS) score was 3.5 and her MS impairment scale (MSIS) score was 31 [4]. Following HCT she had new MRI disease activity and showed EDSS progression due to impairment of walking ability, which according to the patient partially resulted from pain after a deep venous thrombosis of the leg (table 1). Her MSIS score, which quantitates abnormalities on a standard neurological examination, also increased after HCT, but improved at later follow-up visits.

Before HCT she had IgG oligoclonal bands in cerebrospinal fluid (CSF) (fig. 1). B cell chemokine CXCL13 and matrix metalloproteinase-9 (MMP-9) levels in CSF, measured with commercially available ELISA kits (R&D Systems, Abingdon, UK), were normal.

One-year post-transplant CSF examination was negative for oligoclonal bands, and MMP-9 levels were normal, but CXCL13 was detectable (fig. 1 and table 1). In April 2010 IgG oligoclonal bands remained absent, but CXCL13 was still detectable and the MMP-9 concentration had increased (table 1). CXCL13 concentrations were not measured in serum or plasma samples. Therefore, it cannot be excluded that CXCL13 in CSF might arise from plasma. Previous studies of CXCL 13 have, however, not detected CXCL3 in plasma in sufficiently high concentrations to have an impact on the CXCL13 concentrations measured in CSF [5]. We therefore consider it most likely that the CXCL13 measured in CSF arises from local synthesis. Furthermore, a polyclonal intrathecal IgG synthesis occurring in the absence of oligoclonal IgG synthesis is a theoretical possibility, but would be highly unusual in the setting of MS [6].

Discussion

The relationship between inflammation, demyelination and axonal pathology in MS is not resolved. Inflammation in relapsing-remitting MS is associated with demyelination and axonal loss. In progressive MS this relationship is less clear and it is thought that axonal degeneration may continue in the absence of overt inflammation [7], however, recent studies challenge this notion [8].
A handful of cases of MS patients treated with allo-HCT for malignant hematological disease have been published [1]. In two recent reports continued disease activity was observed after transplantation [9, 10]. In our patient allo-HCT was associated with the disappearance of IgG oligoclonal bands. This has also been observed in auto-HCT-treated MS patients [2]. However, serial CSF studies showed that even though IgG oligoclonal bands disappeared, CXCL13 and MMP-9 concentrations were increased. CXCL13 is expressed in perivascular infiltrates and within the brain parenchyma in MS, and CSF concentrations of CXCL13 are increased in secondary progressive MS [5, 11]. Secondary progressive MS patients with a more severe disease course harbor lymphoid follicle-like structures in the meninges, and CXCL13 may be involved in the generation of these structures [12]. MMP-9 in CSF has also been associated with disease activity in MS [13]. In an autopsy study it was observed that although lymphocytes and plasma cells were almost absent after auto-HCT, there was ongoing microglia activation, demyelination, and axonal pathology [14]. We hypothesize that CXCL13 and MMP-9 detected in the CSF of our patient may reflect ongoing, pathogenic, immune activation associated with continuing tissue damage even after the eradication of intrathecal IgG synthesis. This is consistent with the notion that progressive MS may depend more on innate than on adaptive immune activation [8, 15].

**Disclosure Statement**

The authors declare that they have no conflicts of interest.
### Table 1. Overview of events, treatment, scores, paraclinical, and clinical findings

<table>
<thead>
<tr>
<th>Date</th>
<th>Clinical events</th>
<th>Treatment</th>
<th>EDSS score</th>
<th>MSIS score</th>
<th>MRI</th>
<th>Oligoclonal bands</th>
<th>CXCL13</th>
<th>MMP-9</th>
</tr>
</thead>
<tbody>
<tr>
<td>1985</td>
<td>MS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nov. 2003</td>
<td>follicular lymphoma</td>
<td>CVP, FC</td>
<td>3.5</td>
<td>31</td>
<td>&gt;10 T2 brain lesions, spinal MRI not done</td>
<td>positive</td>
<td>undetectable</td>
<td></td>
</tr>
<tr>
<td>June 2006</td>
<td>CR of lymphoma</td>
<td>FA, TBI, CsA, MMF³</td>
<td>3.5</td>
<td>30</td>
<td>&gt;10 T2 brain lesions, spinal MRI not done</td>
<td>positive</td>
<td>undetectable</td>
<td></td>
</tr>
<tr>
<td>July 2006</td>
<td>Allo-HCT</td>
<td>GA, MMF</td>
<td>3.5</td>
<td>30</td>
<td>&gt;10 T2 brain lesions, spinal MRI not done</td>
<td>positive</td>
<td>undetectable</td>
<td></td>
</tr>
<tr>
<td>Aug. 2006</td>
<td>acute GVHD</td>
<td>MEP, CsA, MMF, Infliximab</td>
<td>4</td>
<td>39</td>
<td>several new brain lesions and 2 spinal cord lesions</td>
<td>negative</td>
<td>undetectable</td>
<td></td>
</tr>
<tr>
<td>April 2007</td>
<td>CR of lymphoma</td>
<td>MEP, MMF, PSL</td>
<td>5</td>
<td>33</td>
<td>several new brain lesions and 2 spinal cord lesions</td>
<td>negative</td>
<td>undetectable</td>
<td></td>
</tr>
<tr>
<td>Sept. 2007</td>
<td>acute GVHD resolved/</td>
<td>MEP, PSL, MMF, TAC</td>
<td>5</td>
<td>33</td>
<td>several new brain lesions and 2 spinal cord lesions</td>
<td>negative</td>
<td>undetectable</td>
<td></td>
</tr>
<tr>
<td>July 2008</td>
<td>chronic GVHD</td>
<td>PSL, TAC, MMF</td>
<td>5</td>
<td>33</td>
<td>several new brain lesions and 2 spinal cord lesions</td>
<td>negative</td>
<td>undetectable</td>
<td></td>
</tr>
<tr>
<td>Aug. 2008</td>
<td>CR of lymphoma</td>
<td>PSL, TAC, MMF</td>
<td>5</td>
<td>33</td>
<td>several new brain lesions and 2 spinal cord lesions</td>
<td>negative</td>
<td>undetectable</td>
<td></td>
</tr>
<tr>
<td>Sept. 2008</td>
<td>acute GVHD</td>
<td>PSL, TAC, MMF</td>
<td>5</td>
<td>33</td>
<td>several new brain lesions and 2 spinal cord lesions</td>
<td>negative</td>
<td>undetectable</td>
<td></td>
</tr>
<tr>
<td>Dec. 2008</td>
<td>acute GVHD</td>
<td>PSL, TAC, MMF</td>
<td>5</td>
<td>33</td>
<td>several new brain lesions and 2 spinal cord lesions</td>
<td>negative</td>
<td>undetectable</td>
<td></td>
</tr>
<tr>
<td>April 2010</td>
<td>acute GVHD</td>
<td>TAC</td>
<td>5</td>
<td>33</td>
<td>several new brain lesions and 2 spinal cord lesions</td>
<td>negative</td>
<td>undetectable</td>
<td></td>
</tr>
<tr>
<td>June 2010</td>
<td>TAC</td>
<td>5</td>
<td>33</td>
<td></td>
<td>several new brain lesions and 2 spinal cord lesions</td>
<td>negative</td>
<td>undetectable</td>
<td></td>
</tr>
<tr>
<td>May 2011</td>
<td>TAC</td>
<td>5</td>
<td>33</td>
<td></td>
<td>several new brain lesions and 2 spinal cord lesions</td>
<td>negative</td>
<td>undetectable</td>
<td></td>
</tr>
</tbody>
</table>

¹The patient has been receiving immunoglobulin replacement therapy since July 2006 due to hypogammaglobulinemia.

MRI = Magnetic resonance imaging; CXCL13 = C-X-C motif chemokine 13 (undetectable, i.e., <7.8 pg/ml in control subjects); MMP-9 = matrix metalloproteinase-9 (undetectable, i.e., <0.0312 ng/ml in control subjects); GVHD = graft-versus-host disease; CR = complete remission; CVP = cyclophosphamide, vincristine, prednisolone; FC = fludarabine, cyclophosphamide; FA = fludarabine; TBI = total body irradiation; MEP = methylprednisolone; CsA = cyclosporine A; PSL = prednisolone; MMF = mycophenolate mofetil; TAC = tacrolimus.
**Fig. 1.** Results of isoelectric focusing of IgG in CSF and serum from 2006 (before transplantation) and after transplantation in 2008 and 2010. The anode of the gel is at the bottom of the gel and the cathode is at the top of the gel. Oligoclonal bands are depicted by arrowheads. IgG oligoclonal bands were studied by isoelectric focusing in a commercially available isoelectric focusing gel followed by immunofixation with anti-IgG antibody and protein staining of fixed IgG-anti-IgG complexes in the gel (Hydragel CSF isofocusing, Sebia Electrophoresis, Norcross, USA).

**References**


